Compare MINISO Group Holding Ltd (MNSO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Sanofi SA — how do they compare? MINISO Group Holding Ltd trades at $9.62 (market cap $2.65B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 35.9× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (7.34%). Which is the better fit depends on your goals — on Pluang, investors hold MINISO Group Holding Ltd for 25 Days and Sanofi SA for 94 Days on average.
| MNSO | SNY | |
|---|---|---|
Market Cap | $2.65B | $95.18B |
Volume | 747,763 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.75 | $52.34 |
52-Week Low | $8.60 | $39.51 |
Typical Hold Time | 25 Days | 94 Days |
Enterprise Value | $3.52B | $114.48B |
Dividend Yield | 7.34% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages and a mixed earnings history. The company reported 2025 revenue of $21.44 billion and net income of $1.21 billion, with a P/E of 14.76 and P/S of 0.79 indicating reasonable valuation. Recent news highlights CFO share purchases and earnings volatility, with analyst consensus leaning bullish at 60% buy ratings.
The outlook for MNSO balances growth potential from domestic expansion against earnings inconsistency and competitive pressures. Investment appeal lies in its value metrics and operational scale, but risks include margin compression and market sentiment shifts. The stock's near-term direction hinges on sustained profitability improvements and macroeconomic conditions.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
